Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- The Kirklin Clinic at Acton Road — Birmingham, Alabama
- Lewis and Faye Manderson Cancer Center — Tuscaloosa, Alabama
+ 399 more sites in the U.S.
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 371 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Locations: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- Kaiser Permanente Dublin — Dublin, California
+ 207 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Locations: - Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
- Highlands Oncology Group - Rogers — Rogers, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
+ 171 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Locations: - Arizona Clinical Trials — Chandler, Arizona
- Arkansas Urology — Little Rock, Arkansas
- MemorialCare Orange Coast Medical Center — Fountain Valley, California
+ 56 more sites in the U.S.
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Locations: - University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
- Stanford Cancer Center ( Site 0036) — Palo Alto, California
- Kaiser Permanente Riverside Medical Center ( Site 0099) — Riverside, California
+ 45 more sites in the U.S.
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Locations: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Locations: - City of Hope Cancer Center Phoenix — Goodyear, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
- City of Hope National Medical Center — Duarte, California
+ 42 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Locations: - Highlands Oncology Group — Fayetteville, Arkansas
- VA Greater LA Healthcare System — Los Angeles, California
- VA Palo Alto Health Care System — Palo Alto, California
+ 36 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression f…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06855277
Locations: - Urology Centers Of Alabama Pc — Homewood, Alabama
- Univ Cali Irvine ALS Neuromuscular — Orange, California
- Stanford University Medical Center — Palo Alto, California
+ 35 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Locations: - Honor Health Research Institute — Scottsdale, Arizona
- VA Greater LA Healthcare System — Los Angeles, California
- VA Palo Alto Health Care System — Palo Alto, California
+ 32 more sites in the U.S.
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Locations: - University of Alabama Birmingham Hospital — Birmingham, Alabama
- Mayo Clinic- Phoenix — Phoenix, Arizona
- Arkansas Urology Research Center, LLC — Little Rock, Arkansas
+ 26 more sites in the U.S.